Type of leukemia-Chronic lymphocytic leukemia (CLL) Posts on Medivizor

Posted by Medivizor on Sep 27, 2022 in Leukemia | 0 comments

In a nutshell The study aimed to investigate if anti-CD19 chimeric antigen receptor (CAR) T-cell therapy and ibrutinib (Imbruvica) could be combined for the treatment of patients with chronic lymphocytic leukemia (CLL).   This study concluded that adding anti-CD19 CAR T-cell therapy (CART-19) to ibrutinib treatment in these patients...

Posted by Medivizor on May 31, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate infusion reactions and the effectiveness of the combination of obinutuzumab (Gazyva) and chlorambucil (Leukeran) in patients with chronic lymphocytic leukemia (CLL).  This study concluded that first dose infusion reactions with obinutuzumab can be reduced by using chlorambucil first and by using a very...

Posted by Medivizor on Dec 31, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate minimal residual disease (MRD) and long-term outcomes of patients with chronic lymphocytic leukemia (CLL) who were treated with venetoclax (Venclexta) and obinutuzumab (Gazyva).  This study concluded that this treatment leads to an effective MRD reduction and has...

Posted by Medivizor on Aug 1, 2021 in Leukemia | 0 comments

In a nutshell This review aimed to compare the benefits and risks associated with targeted therapy (TT) and chemoimmunotherapy (CIT) as frontline treatments for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).  Some background The number of treatment options for CLL and SLL has increased in the last few years....

Posted by Medivizor on May 8, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if acalabrutinib (Calquence) was suitable for patients with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL) who are intolerant to ibrutinib (Imbruvica).   This study concluded that acalabrutinib was effective and well tolerated in these patients.   Some...